Both times, Amgen used the bulk of the proceeds to protect its share price through stock buybacks. Gilead Sciences and MedImmune ... as well as Biogen Idec (Cambridge, MA, USA) and MedImmune ...

Two specialists are impressed by the preliminary findings of a randomized trial in newly diagnosed patients, but another is ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Biotechnology is at the forefront of innovation, transforming healthcare and pushing the boundaries of what’s possible. As groundbreaking discoveries unfold daily—from cutting-edge therapies to ...

Correspondence to Dr Laurent Peyrin-Biroulet, Department of Gastroenterology, INFINY Institute, Nancy University Hospital Center, Vandœuvre-lès-Nancy, Grand Est, France; peyrinbiroulet{at}gmail.com ...

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile ...

Yee covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Amgen, and Moderna. Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $83.56.